Back to articles

Anastrozole lowers breast cancer incidence in high-risk women


In postmenopausal women at high risk for breast cancer, preventive treatment with anastrozole (Arimidex—AstraZeneca) for 5 years reduced the incidence of breast cancer by about 50% compared to placebo. Mortality rates in anastrozole and placebo groups were similar at 5 years, but anastrozole was associated with increased incidence of musculoskeletal and vasomotor symptoms, carpal tunnel syndrome, and hypertension.